This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Baptista Freitas M, Desmyter L, Badoer C, Smits G, Vandernoot I, T’Kint de Roodenbeke D. POT1 tumour predisposition: a broader spectrum of associated malignancies and proposal for additional screening program. Eur J Hum Genet. 2024. https://doi.org/10.1038/s41431-024-01611-0.
Robles-Espinoza CD, Harland M, Ramsay AJ, Aoude LG, Quesada V, Ding Z, et al. POT1 loss-of-function variants predispose to familial melanoma. Nat Genet. 2014;46:478–81.
Herrara-Mullar J, Fulk K, Brannan T, Yussuf A, Polfus L, Richardson ME, et al. Characterisation of POT1 tumor predisposition syndrome: tumor prevalence in a clinically diverse hereditary cancer cohort. Genet Med. 2023;25:100937.
DeBoy EA, Tassia MG, Schratz KE, Yan SM, Cosner ZL, McNally EJ, et al. Familial clonal hematopoiesis in a long telomere syndrome. N Engl J Med. 2023;388:2422–33.
Henry M-L, Osborne J, Else T. POT1 tumor predisposition. Gene Rev. 2022. https://www.ncbi.nlm.nih.gov/books/NBK563529/
Author information
Authors and Affiliations
Contributions
The authors contributed equally to drafting and finalizing the commentary.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ballinger, M.L., Thomas, D.M. POT1 clinical risk management is an open question. Eur J Hum Genet (2024). https://doi.org/10.1038/s41431-024-01676-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41431-024-01676-x